Novel drug inhibits liver damage, obesity and glucose intolerance in mice fed with high-fat diet
For this, they first built a customized dual AAV vector that contained Cas9, a bacterial protein that is guided by RNA to identify and edit genes within cells rapidly. This new vector is called AAV8, and it migrates explicitly towards the liver cells. The second AAV has a minigene that contains the donor DNA encoding the human OTC enzyme. This functional minigene is regulated by a promoter sequence that is specific to liver cells. This safeguard ensures that it will be expressed only within liver cells after being injected into the blood via the AAV.
The Cas9 first nicks the DNA strand at the target site within the gene sequence. This is the "cut" part of the process and is followed by the "paste," where the minigene is added via a repair process called homology-directed repair.
The addition allowed the newborn mice to develop in a much healthier manner. At three weeks of life, 25% of the liver cells were expressing OTC, and at 8 weeks, 35% were showing this expression. This may seem like a modest difference, but is still three and four times the effect produced by the use of the untargeted vector at these time points, respectively.
When the liver was examined at these time points, the researchers found clusters of OTC-producing cells situated throughout the liver more or less uniformly. The difference persisted into adult life. Even on a high-protein diet, the targeted mice showed ammonia levels 60% lower than in untreated mice. The implications
The difference is explained by another researcher, Lili Wang: "Unlike other CRISPR approaches that delete or modify a portion of the normal gene, this technique integrates a new portion. We're not trying to correct mutations that stop liver cells from producing OTC; we're adding this new minigene so the cells can."
The study shows that this new CRISPR-based technique may be adapted to prevent the clinical manifestations of a rare genetic condition caused by multiple mutations. It could also be used to alleviate other hereditary conditions caused by other mutations of the same gene. The critical feature of this approach is that it uses one strategy to combat a condition caused by a number of mutations at different parts of the genome, and not just one chief mutation.
Researcher James Wilson explains: "Here, we moved a CRISPR approach forward to not only sustain expression of OTC in the cells but also broaden the tool's abilities. We've moved closer to a potential 'broad spectrum' gene-editing approach to treat patients with the OTC deficiency, irrespective of mutation and clinical state. The next step, through additional preclinical studies, is to find a safe harbor site on the gene in human liver cells and then to test a similar gene-editing approach." Journal reference:
A mutation-independent CRISPR-Cas9–mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency, Lili Wang, Yang Yang, Camilo Breton, Peter Bell1, Mingyao Li, Jia Zhang, Yan Che, Alexei Saveliev, Zhenning He, John White, Caitlin Latshaw, Chenyu Xu, Deirdre McMenamin, Hongwei Yu, Hiroki Morizono, Mark L. Batshaw and James M. Wilson, Science Advances 12 Feb 2020, Vol. 6, no. 7, eaax5701, DOI: 10.1126/sciadv.aax5701
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology